Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Top Page
Wuxi Biologics (Cayman)
(2269)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$39.00
▲(11.49% Upside)
Action:DowngradedDate:11/18/25
Wuxi Biologics' strong financial performance is a significant positive factor, showcasing robust growth and a stable financial position. However, technical analysis indicates bearish momentum, and the valuation suggests the stock may be overvalued. The lack of earnings call data and corporate events limits additional insights.
Positive Factors
Revenue Growth
Sustained >20% CAGR across 2019–2024 indicates durable demand for Wuxi's CDMO services and expanding client adoption. Long-term growth supports higher capacity utilization, recurring service revenue, and justifies continued capital investment in facilities and tech to capture future biologics demand.
Negative Factors
Free Cash Flow Variability
Volatile FCF history despite recent improvement means cash generation is sensitive to timing of contracts and capex cycles. That variability can constrain organic funding for large-scale capacity additions, making the company more reliant on external financing or equity to finance sustained growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained >20% CAGR across 2019–2024 indicates durable demand for Wuxi's CDMO services and expanding client adoption. Long-term growth supports higher capacity utilization, recurring service revenue, and justifies continued capital investment in facilities and tech to capture future biologics demand.
Read all positive factors
Wuxi Biologics (Cayman) (2269) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$144.73B
Dividend YieldN/A
Average Volume (3M)32.67M
Price to Earnings (P/E)11.1
Beta (1Y)1.73
Revenue Growth16.90%
EPS Growth63.11%
CountryHK
Employees12,575
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.70
Shares Outstanding4,137,541,000
10 Day Avg. Volume33,789,006
30 Day Avg. Volume32,668,415
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.61
Price to Sales (P/S)3.60
P/FCF Ratio52.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$45.14Price Target Upside29.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.31
Revenue Forecast (FY)HK$25.28B
Wuxi Biologics (Cayman) Business Overview & Revenue Model
Company Description
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision...
How the Company Makes Money
Wuxi Biologics generates revenue primarily through its contract development and manufacturing organization (CDMO) services, which include process development, clinical and commercial manufacturing of biologics. The company typically enters into lo...
Wuxi Biologics (Cayman) Financial Statement Overview
Summary
Income Statement
87
Very Positive
Balance Sheet
82
Very Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.05B | 18.68B | 17.03B | 15.27B | 10.29B | 5.61B |
| Gross Profit | 8.55B | 7.65B | 6.83B | 6.72B | 4.83B | 2.53B |
| EBITDA | 7.41B | 6.43B | 5.50B | 6.22B | 4.51B | 2.31B |
| Net Income | 4.20B | 3.36B | 3.40B | 4.42B | 3.39B | 1.69B |
Balance Sheet | ||||||
| Total Assets | 60.44B | 56.98B | 56.58B | 49.56B | 44.03B | 28.96B |
| Cash, Cash Equivalents and Short-Term Investments | 12.54B | 10.71B | 11.24B | 8.71B | 11.13B | 8.48B |
| Total Debt | 5.11B | 4.94B | 4.56B | 4.42B | 4.30B | 3.33B |
| Total Liabilities | 11.37B | 11.50B | 12.56B | 13.35B | 11.33B | 8.06B |
| Stockholders Equity | 44.95B | 41.82B | 40.33B | 35.05B | 32.28B | 20.56B |
Cash Flow | ||||||
| Free Cash Flow | 1.76B | 1.29B | 437.20M | -326.72M | -3.09B | -4.14B |
| Operating Cash Flow | 5.72B | 5.22B | 4.67B | 5.54B | 3.43B | 1.88B |
| Investing Cash Flow | -4.10B | -3.94B | -3.23B | -5.91B | -9.60B | -7.22B |
| Financing Cash Flow | -2.36B | -2.75B | 1.96B | -2.59B | 8.21B | 6.57B |
Wuxi Biologics (Cayman) Technical Analysis
Positive
34.98
Price Trends
36.87
Negative
35.27
Negative
34.03
Positive
Market Momentum
-1.01
Negative
50.39
Neutral
72.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2269, the sentiment is Positive. The current price of 34.98 is above the 20-day moving average (MA) of 34.25, below the 50-day MA of 36.87, and above the 200-day MA of 34.03, indicating a neutral trend. The MACD of -1.01 indicates Negative momentum. The RSI at 50.39 is Neutral, neither overbought nor oversold. The STOCH value of 72.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2269.
Wuxi Biologics (Cayman) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$64.41B | 9.63 | 14.85% | 0.95% | 7.51% | 44.09% | |
63 Neutral | HK$144.73B | 11.12 | 10.55% | ― | 16.90% | 63.11% | |
61 Neutral | HK$113.21B | 43.78 | 11.85% | 1.40% | 13.69% | 50.71% | |
61 Neutral | HK$158.77B | 144.97 | 4.82% | ― | 52.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.64B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$129.42B | -84.52 | -14.40% | ― | 33.46% | -7.60% |
* Healthcare Sector Average
HK:2269
Wuxi Biologics (Cayman)
34.98
16.70
91.36%
HK:1177
Sino Biopharmaceutical
6.33
3.04
92.17%
HK:1801
Innovent Biologics
91.50
51.85
130.77%
HK:1530
3SBio
25.38
15.34
152.81%
HK:9926
Akeso, Inc.
140.50
75.75
116.99%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.70
108.04%
Wuxi Biologics (Cayman) Corporate Events
WuXi Biologics’ Substantial Shareholder to Cut Stake via HK$38.52 Block Trade
Jan 15, 2026
WuXi Biologics announced that substantial shareholder WuXi Biologics Holdings Limited has agreed to sell 150 million existing shares, or about 3.63% of the company’s issued share capital, via a block trade arranged by Morgan Stanley at HK$38...
Citigroup-Backed HK$4.00 Cash Offer Launched for Wuxi Biologics Shares at 99% Premium
Jan 14, 2026
Citigroup Global Markets Asia will, on behalf of an unnamed offeror, launch a voluntary conditional cash offer for all issued shares of Wuxi Biologics (Cayman) not already owned by the offeror and its concert parties, as well as a related offer to...
WuXi Biologics Highlights Strong 2025 Pipeline and Growth Ahead of J.P. Morgan Healthcare Conference
Jan 11, 2026
WuXi Biologics announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on 14 January 2026, using the forum to share detailed information on its business operations and recent performance with global investors. The compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.